// // It is highly recommended to set this option, even though it's not required. // defaults to undefined. //appElement: "#page-container", // Optional. You can customize the name of the cookie that Orejime uses for storing // user consent decisions. // defaults to "orejime". cookieName: "diadao_cookies", // Optional. You can set a custom expiration time for the Orejime cookie, in days. // defaults to 365. cookieExpiresAfterDays: 365, // You must provide a link to your privacy policy page privacyPolicy: JSON.parse(Config.orejimePrivacyPolicyPage), // You must provide a link to your cookies policy page cookiePolicy: JSON.parse(Config.orejimeCookiesPage), // Optional. Applications configured below will be ON by default if default=true. // defaults to true default: true, // Optional. If "mustConsent" is set to true, Orejime will directly display the consent // manager modal and not allow the user to close it before having actively // consented or declined the use of third-party apps. // defaults to false mustConsent: false, // Optional. If "implicitConsent" is set to true, Orejime will automatically accept // cookies if the user continues his navigation on the website after the // first page. If you enable this, you must warn the user // of this behavior in the notice window. You can do that easily by overriding // translation strings (see below). // defaults to false implicitConsent: false, // Optional. You can define the UI language directly here. If undefined, Orejime will // use the value given in the global "lang" variable, or fallback to the value // in the lang attribute, or fallback to "en". lang: Config.currentLang, // You can overwrite existing translations and add translations for your // app descriptions and purposes. See `src/translations.yml` for a full // list of translations that can be overwritten // translations: Config.texts.orejime, // If you want to use custom text for your project translations: {}, // The list of third-party apps that Orejime will manage for you. // The apps will appear in the modal in the same order as defined here. // appsList: ["analytics", "big_calendar", "orejime", "offerhighlight"], appsList: JSON.parse(Config.orejimeAppsList), apps: [] }

Reveal the invisible.
Save lives.

Innovate. Save lives.

Make informed, more efficient clinical decisions

Each and every day, we push the boundaries of innovation with solutions that help save lives.

Our solutions

MYRIAN

Myrian, perfectly orchestrated advanced visualization
DISCOVER MYRIAN

LIFLOW

Liflow, the 1st intelligent oncology analysis platform
DISCOVER LIFLOW

Why choose Intrasense solutions?

Focus on what’s important

Achieve faster interpretation and more effective follow-up with our AI-enriched software solutions, featuring optimized ergonomics.

Use advanced, fully integrated visualisation tools

Build feature-rich clinical apps and the best artificial intelligence systems directly into your workflow.
Request a demo

Natively integrated artificial intelligence

At a time when the world of medical imaging is all about artificial intelligence, our aim is to bring it within your reach!

Our technology lets radiologists and clinicians focus on quality of care by building artificial intelligence systems into their workflow, all with a focus on clinical needs.

Our natively AI-powered clinical apps are built to the highest clinical standards.

Innovative, collaborative solutions fully integrated into any healthcare information system

20 years
of innovation
1,200 customers
worldwide

70 employees
committed to saving lives
170 scientific papers
and several technology patents

Intrasense news

Intrasense presents its AI innovations at the SIRM congress in Italy

10 June 2024
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow®, announces its participation in SIRM, the congress organized by the Italian Society of Medical and Interventional Radiology, to be held from June 20 to 23 in Milan (Italy).
Find out more

Intrasense announces CE certification of Liflow® to the new European regulation (MDR)

29 April 2024
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow®, is proud to announce that the company has obtained CE certification under MDR (European Union Medical Device Regulation 2017/745), for the first version of its Liflow® solution.
Find out more

Intrasense announces the appointment of Jérôme Thiebaud as Chief Business Officer

24 April 2024
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow®, announces the appointment of Jérôme Thiebaud as the Group's Chief Business Officer.
Find out more

Presentation of annual results for 2023 and ambitions for 2024

22 April 2024
Intrasense presents its 2023 annual results.Discover in this webinar the progress of Intrasense's medical imaging solutions, its 2024 objectives and ambitions.
Find out more

Liflow®: an innovative AI-enhanced solution to optimize oncology follow-up

16 April 2024
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow®, announces the regulatory submission of its Liflow® 1.0 solution (registered trademark of the Myra project), an oncology platform dedicated to the analysis of diagnostic imaging and cancer follow-up.
Find out more

Intrasense and Guerbet announce CE certification of Myrian 2.12, enhanced with Guerbet's prostate AI

8 April 2024
Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and developer of Myrian®, and Guerbet (FR0000032526 GBT), world leader in medical imaging, are proud to announce that the Myrian® 2.12 platform has obtained CE certification under MDR, integrating prostate AI developed by Guerbet, the Veolity® LungCAD AI developed by MeVis Medical Solutions AG […]
Find out more

2023 annual results

20 March 2024
Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and the developer of Myrian® (the "Company"), today announced its annual 2023 IFRS consolidated financial results certified at Group level.
Find out more

Intrasense presents its innovations at the European Congress of Radiology (ECR) 2024

26 February 2024
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian®, announces its participation at the ECR from February 28 to March 3, in Vienna (Austria).
Find out more

Intrasense announces the certification of Myrian® to the new European regulation (MDR)

21 February 2024
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian®, is proud to announce that the company has obtained the new CE certification under MDR (European Union Medical Device Regulation 2017/745), authorizing the marketing of the latest version of its Myrian® solution.
Find out more

Intrasense announces annual revenue for 2023

8 February 2024
Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and developer of Myrian® (the "Company"), today announced its 2023 consolidated IFRS revenue (uncertified) at Group level.
Find out more

Intrasense announces its financial agenda for 2024

31 January 2024
Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions, announces the dates of its next financial communications for the year 2024.
Find out more

Intrasense announces strategic partnership with EDL, French leader in digital healthcare solutions

18 October 2023
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and designer of Myrian®, has announced the signature of a strategic partnership with EDL. French leader in software packages for technical platforms of public and private healthcare establishments, EDL develops Xplore®, a radiology solution. This partnership will enable the integration and marketing of Myrian® clinical […]
Find out more

2023 Half-year results: sales growth and continued investment policy

20 September 2023
Intrasense (FR0011179886 - ALINS), spécialiste des solutions logicielles d’imagerie médicale et concepteur de Myrian®, annonce ses résultats semestriels 2023 consolidés aux normes IFRS. Etant précisé que suite à l’OPA volontaire du groupe Guerbet, clôturée en date du 5 juin 2023, le groupe Intrasense est maintenant intégré dans le périmètre de consolidation du groupe Guerbet.
Find out more

Intrasense attends the 2023 « Journées Francophones de Radiologie »

13 September 2023
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian®, announces its attendance in the 2023 “Journées Francophones de la Radiologie” (JFR), where new innovative solutions incorporating artificial intelligence will be presented.
Find out more

Intrasense signs a strategic contract with Ebit to market its solutions in Italy

11 July 2023
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian®, and Ebit, part of the italian group Esaote, specialized in the development of software solutions for diagnostic imaging, announce their strategic partnership to market Intrasense solutions in Italy.
Find out more

Intrasense and Guerbet sign a licensing and integration agreement for artificial intelligence in oncology medical imaging

19 June 2023
Intrasense (FR0011179886 - ALINS), spécialiste des solutions logicielles d’imagerie médicale et concepteur de Myrian®, et Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, announce the signature on June 19, 2023 of a license agreement to integrate and market Guerbet's artificial intelligence algorithms within Intrasense software platforms.
Find out more

Intrasense announces the co-option of a new director and the appointment of a new Chairman of its Board of Directors

25 May 2023
Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions, annonces, the co-option of a new director to the Board, also appointed Chairman of the Board.
Find out more

2022 annual results: continued investments and renewed growth ambition

30 March 2023
Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and designer of Myrian® (the "Company"), today announced its consolidated (unaudited) 2022 IFRS financial results at Group level.
Find out more

Intrasense strengthens its porfolio with the signature of a contract with SATT Sud-Est

27 March 2023
Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions, announces the signature of a technology transfer contract with SATT Sud-Est that will allow the company to acquire artificial intelligence algorithms dedicated to the detection of pulmonary nodules in radiology. These algorithms were developed by the Medical Imaging Unit of the Assistance Publique-Hôpitaux de […]
Find out more

Intrasense and the ICM sign a partnership to optimize a new solution dedicated to oncology

6 February 2023
Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions, has joined forces with the Montpellier Cancer Institute (ICM) through a partnership aimed at validating and then deploying its new platform dedicated to oncology in real-life situations, with the objective of using it in clinical routine.
Find out more
1 2 3 6